EDAP TMS SA current report, Q4 FY2025

EDAP TMS SA - Form 6-K Summary

Business Context and Reporting Period

This Form 6-K, filed on November 18, 2025, presents an investor presentation for EDAP TMS SA, a French company specializing in therapeutic ultrasound. The financial data covers the three and nine months ended September 30, 2025. The company positions itself as the global leader in robotic High-Intensity Focused Ultrasound (HIFU) for the treatment of prostate cancer, Benign Prostatic Hyperplasia (BPH), and endometriosis.

Key Financial Metrics

Three Months Ended September 30, 2025 (vs. 2024):

  • Revenue: $16.1 million (up from $14.4 million).
  • Gross Profit: $6.9 million (up from $5.7 million).
  • Gross Margin: 43.0% (up from 39.4%).
  • Operating Loss: $(5.7) million (improved from $(6.4) million).
  • Net Loss: $(5.8) million (improved from $(7.0) million).
  • EPS: $(0.16) (improved from $(0.19)).

Nine Months Ended September 30, 2025 (vs. 2024):

  • Revenue: $48.8 million (up from $47.6 million).
  • Gross Profit: $20.7 million (up from $19.0 million).
  • Gross Margin: 42.5% (up from 39.9%).
  • Operating Loss: $(18.7) million (worsened from $(18.2) million).
  • Net Loss: $(19.8) million (worsened from $(18.5) million).
  • EPS: $(0.53) (worsened from $(0.50)).

Balance Sheet Highlights (as of Sept 30, 2025):

  • Cash and Cash Equivalents: $12.4 million (down from $28.4 million in Sept 2024).
  • Total Assets: $72.1 million (down from $88.1 million).
  • Shareholders' Equity: $27.4 million (down from $47.5 million).

Material Changes and Segment Performance

The company reported divergent performance across its product lines:

  • HIFU Segment: Demonstrated strong growth. Three-month revenue increased 57% to $4.9 million. Nine-month revenue decreased 32% to $16.3 million compared to $23.9 million in the prior year, though the presentation highlights a 46% growth metric in a chart context which may refer to a specific sub-period or adjusted figure; the table explicitly shows a decline in the 9-month aggregate.
  • Distribution Segment: Declined 14% in the three months ($6.3M vs $7.3M) and 21% in the nine months ($19.1M vs $24.1M).
  • ESWL Segment: Relatively stable, with a 4% decline in the three months ($2.1M vs $2.2M) and a 20% decline in the nine months ($5.7M vs $7.1M).
  • Liquidity: Cash reserves decreased significantly by approximately $16 million over the nine-month period, reducing the cash position from $28.4 million to $12.4 million.

Outlook, Management Commentary, and Risks

Strategic Focus and Clinical Evidence:

  • Prostate Cancer: The company highlights the "HIFI" study (published Dec 2024) showing HIFU has comparable cancer control to radical prostatectomy (90% vs 86%) with superior functional outcomes (urinary continence and erectile function). The "FARP" randomized trial also showed equivalent oncologic control at 3 years.
  • Reimbursement: CMS maintained HIFU at APC Level 6 for 2025, with hospital payments of $12,992 and physician payments of $951, described as favorable compared to other modalities.
  • Expansion: The company is expanding into BPH and Endometriosis. A Phase III study for endometriosis completed enrollment in March 2025. BPH studies are in Phase I/II.
  • Install Base: As of September 30, 2025, there are 76 Focal One systems in the U.S. (39 academic, 37 community). The U.S. installation base has grown at a 51% CAGR (2021-2024).

Risks and Contingencies:

  • Cash Burn: The significant reduction in cash and cash equivalents ($16M drop in 9 months) against a net loss of nearly $20M raises liquidity concerns.
  • Revenue Volatility: While the most recent quarter showed growth, the nine-month HIFU revenue declined year-over-year, indicating potential seasonality or execution challenges in the broader period.
  • Regulatory/Market Adoption: Success depends on continued reimbursement stability and the successful translation of clinical trial data into widespread physician adoption.

Investor Verification Checklist

  • Liquidity Runway: Verify the company's cash burn rate and whether the $12.4M cash balance is sufficient to fund operations and R&D without immediate dilution or debt.
  • HIFU Revenue Trend: Reconcile the 57% quarterly growth with the 32% nine-month decline in HIFU revenue to understand the underlying demand trajectory.
  • Reimbursement Stability: Confirm the long-term sustainability of the APC Level 6 reimbursement status in the U.S. market.
  • Clinical Trial Outcomes: Monitor the release of final data from the Phase III Endometriosis trial and the ongoing BPH Phase II study.
  • Install Base Conversion: Assess the procedure volume per installed system to determine if the growing install base is translating into recurring revenue.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.